DelveInsight’s ‘CAR T Pipeline Insight 2022‘ report provides comprehensive global coverage of available, marketed, and pipeline CAR T therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the CAR T pipeline domain.
For CAR T emerging drugs, the CAR T pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Some of the Key Highlights from CAR T Pipeline Report
- Over 460+ CAR T pipeline therapies are in various stages of growth, and their anticipated acceptance in the CAR T market would significantly increase market revenue.
- Leading CAR T companies such as Ziopharm Oncology Inc. and Intrexon, Yake Biotechnology, Xyphos Biosciences, Xi’An Yufan Biotechnology, Wuhan Sian Medical Technology, Wuhan Bio-Raid Biotechnology, Wugen, WindMIL Therapeutics, Wellington Zhaotai Therapies, VorBio, VCANBIO Cell & Gene Engineering Corporation, Ltd, UWELL Biopharma, Transgene, TrakCel, ToolGen, Tmunity Therapeutics, Timmune Biotech, TILT Biotherapeutics, Tianjin Mycure Medical Technology, The Beijing Pregene Science and Technology Company, Tessa Therapeutics Ltd., TC BioPharm, Targazyme, Takeda, Noile-Immune Biotech, Synthekine, SymVivo, Sorrento Therapeutics, Sinobioway Cell Therapy Co., Ltd., Shenzhen BinDeBio, Shanghai Unicar-Therapy Bio-medicine Technology, Shanghai Longyao Biotechnology, Shanghai GeneChem Co., Ltd., Shanghai Biomed-union Biotechnology, Servier, Sensei Biotherapeutics, Senlang Bio, Sangamo, Sana Biotechnology, REGENERON, PTX Therapeutics, Protheragen, Pregene (ShenZhen) Biotechnology Company, Precision BioSciences, Precigen, Poseida Therapeutics, PersonGen BioTherapeutics (Suzhou) Co., Ltd., Pepromene bio, Oxford Biomedica, Orgenesis, Oncternal Therapeutics, Novartis Pharmaceuticals, Noile-Immune Biotech, Nanjing KAEDI Biotech, Mustang Bio, MolMed, Minerva Biotechnologies, Miltenyi Biotec, Medisix Therapeutics, Maxcyte, Luminary Therapeutics, Liminatus Pharma, Kuur Therapeutics, Kiromic BioPharma, Kecellitics Biotech Company Ltd, KAEDI, JW Therapeutics, Janssen Pharmaceuticals, Intellia Therapeutics, Innovent Biologics, Innovative Cellular Therapeutics, InnoBation, IN8Bio, Immunicum, Immuneel, Immune Therapeutics, iCell Gene Therapeutics, iCarTAB BioMed, Hunan Zhaotai Yongren Medical Innovation, Humorigin, HRAIN Biotechnology, Henan Hualong Biotechnology, Hemalogix, Helocyte, Helix BioPharma, Hebei Senlang Biotechnology Inc., Ltd., Guangzhou Bio-gene Technology, Guangdong Zhaotai InVivo Biomedicine Co. Ltd., Grand Vista Biotechnology, Gracell Biotechnology, Glycotype, GlaxoSmithKline, Gilead Sciences, Genus oncology, GC Cell, Fundamenta Therapeutics, Fujifilm Holdings Corporation, Formula Pharmaceuticals, Fate Therapeutics, FastBack Bio, Exuma, Eutilex, Utilities, Eureka Therapeutics, Enlivex Therapeutics Ltd, Endocyte, Elpis Biopharmaceuticals, Curocell, CRISPR Therapeutics, Creative Biolabs, Cogent Biosciences, Chongqing Precision Biotechnology Co., Ltd., Chimeric Therapeutics, Celyad Oncology SA, Cellular Biomedicine Group, Cellectis, Celgene, CASI Pharmaceuticals, Juventas Cell Therapy, Cartherics, Cartesian Therapeutics, Carsgen Therapeutics, CARsgen, Carina Biotech, Caribou Biosciences, Bristol-Myers Squibb, BrightPath Therapeutics, Bluebird Bio, Biosceptre, BioNTech, Bioceltech Therapeutics, Bioatla, Benitec Biopharma Limited , Bellicum Pharmaceuticals, Beijing Mario Biotech, Beijing Immunochina Medical Science and Technology, Beijing Doing Biomedical, Beam Therapeutics, Autolus Limited, Aurora Biopharma, Atreca, Xenor, Atossa Therapeutics, Atara Biotherapeutics, Arcellx Inc, Arbele Limited, Apceth Biopharma, Anixa Biosciences, Amgen, Kite Pharma, Allogene Therapeutics, Allife Medical Science and Technology, AgenTus Therapeutics, AffyImmune Therapeutics, Adicet Bio, Adagene, Actinium Pharmaceuticals, AbCLon, AbbVie, Obsidian Therapeutics, Beijing Biohealthcare Biotechnology, and others are evaluating novel CAR T treatment drugs candidate to improve the treatment landscape.
- Key CAR T pipeline therapies in various stages of development include JWCAR029, KTE-X19, Ciltacabtagene autoleucel, CT103A, CEA CAR-T, Descartes-11, CNCT19, CTL119, P-BCMA-101, CD19/CD20/CD22/CD30 CAR T-cell therapy, CD19-targeted CAR T-cells, EPCAM-targeted CAR-T cells, TT11, CD19+CD22 CAR-T cell sequential therapy, CART-19/22, MB-CART2019.1, JCAR017, AUTO4, AUTO3, IM19 CAR-T, CSG-CD19, CT053, Descartes-08, Orvacabtagene autoleucel, CAR-T CD30, PCAR-19B, BCMA CAR-T cells, CD123 CAR-T cells, CD19 CAR-T cells, ET140202, CIK-CAR.CD19, BG-T19, Autologous CD19-targeting CAR T cells (Senl-001), MB-102, Autologous CAR-T CD44v6 cell therapy, AU101, ATA2271, AU105, AUTO1, BPX-601, Anti-CD22 CAR, CAR-T cells targeting CD19 and CD22, huMNC2-CAR44 CAR T-cells, CD19-CART, ALLO-501A, AUTO1/22, ET 1402L1-CART, BPX-603, CAR-CD44v6, MB-106 (CD20 CAR), Anti-MUC1 CAR-T cells, PCAR-019, PBCAR0191, PBCAR20A, PBCAR269A, BCMA CAR T-cells, CAR19 CAR T cells, MG7-CART Cells, GPC3 – CART Cells, Anti-CD19 and Anti-CD20 CAR-T Cells, Humanized CD19 CAR-T cells, Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy, Mesothelin CAR-T cell therapy, TBI-1501, CART-19 cells, EGFR CART, CD19 Chimeric Antigen Receptor (CAR), BNT211, MB-CART19.1, MB-CART20.1, IM19 CAR-T, CD22 CAR-T, CAR-T, iC9-CAR19 cells, JCAR014, GC007g, CD-7 CAR-T Molecule, KD-025 CAR T cells, CD7 CAR T-cells infusion, CRC01, CT041, KD-182 CAR T cells, VCAR33, ICTCAR014, GC022F CAR-T cells, Senl_B19, IM21 CAR-T, CTX101, bb21217, CAR-GPC3, JCAR 018, JCAR020, JCAR024, CD19 Armored CAR, JCAR 023, UCART123, UCART22, UCARTCS1, CYAD-02, C-CAR011, CD20-CD19 Bispecific CAR, GC027, MB-103, UCART19, Cart19, Anti-BCMA CAR-T cell, CD19/CD20 bispecific CAR-T cells, AVA-001, Anti-CD19-CAR, P-PSMA-101, NIB-102, HER2-CAR VST + CAdVEC, CART-ddBCMA, CYAD-101, ET190L1 ARTEMIS, KITE-585, GPC3 targeting CAR-T cells, HER2/Mesothelin/Lewis-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T cell therapy, Triplex+CAR-Ts, Anti-CD19/BCMA Bispecific CAR T-cell Therapy, BCMA Chimeric Antigen Receptor Therapy, Human CD19 Targeted T-cells Injection Therapy, Anti-Meso CAR T cells, Anti-CD123 CAR T cells, Anti-CD22 CAR T cells, Zeushield Cytotoxic T Lymphocytes, CLL1b-CD33b compound CAR, CD19 CARvac cell therapy, BCMA-CD19 cCAR T cells therapy, Anti CD19 CART, Human anti-CD19, CD20 CAR T cells, Anti-CD19 Chimeric Antigen Receptor T cells (KD-019 CAR-T), GUCY2C-Targeted CAR-T Cells, CD19 CAR T-cells, CD70 CAR T-cells, IL3 CAR T-cells, CS1 Targeted CAR T-cells, Murine CD19 CAR T-cells, Humanized CD19 CAR T-cells, CD20/CD22 dual Targeted CAR T-cells, CART-meso, CART-EGFRvIII, CAR T-BCMA, cMet RNA CAR T, CART22 Therapy, BCMA-CART cells, Autologous chimeric antigen receptor T cell transfusing agent targeting CD22, Anti-CD20 CAR-T Cells, CD19 CAR-T cell therapy, Chimeric antigen receptor T cell, CD38 CAR-T, TT11X, Anti-CD19 chimeric antigen receptor T cell therapy, TMUN ONC 001, TMUN ONC 004, CD19 CAR T-cells, CD22 chimeric antigen receptor T cell therapy, CD19 2nd Generation CAR-T Cell Therapy, CD19 3rd Gen with mbIL15 (P-O-C), NKG2D CAR-T Cell Therapy, LMP1 CAR-T cells, APRIL CAR-T cells, CD79b CAR-T Cell Therapy, PRGN-3006, AIC100, ThisCART22, Iomab-ACT Program, ALLO-501, CYAD-211, MCY-M11, PSMA CAR-T -cell immunotherapy, Anti-CD20 CAR, CLBR001 + SWI019, Anti-BCMA CAR T cells, ALLO-715, PRGN-3005, XYF19 CAR-T cell, WU-CART-007, WZTL-002, TI 1007, KUR-501, KUR-502, GC012F, GC019F, GC007F, MB-104, MB-105, MB-101, Chimeric Antigen Receptor T Cell, CTX120, CTX130, BCMA Targeted CAR T-cells, CD19/BCMA Targeted CAR T-cells, TILT-123, CD4CAR, FT-819, CD19/CD20-directed CAR-T cells, CB-010, ALL0-316, ADI-001, KITE-222, JWCAR129, TAK-940, AMG 119, GPRC5D CAR T, Senl_1904B, TILT-T392, TZ-102, PMUC1C-101, P-BCMA-ALLO1, BAFF R CAR-T Cell, ATA3219, Solid Tumor Therapy Program (ovarian cancer), ALL0-605, TAA6-CAR-T, VOR33/ VCAR33, CAR (POC), Myeloid malignancies CAR-T Programme, Merck Target 1, Merck Target 2, Unnamed CAR target, Research programme: CRISPR gene-edited CAR-T cell therapeutics, TMUN ONC 003, IL13 Rα2 CAR-T, PSCA CAR-T, CAR-T Program, CD33HSC/CD33 CAR-T, FAP CAR-T, GPC2 CAR-T, TT14, TCB003, TCB004, TCB005, TCB006, NIB-103, Allogeneic chimeric antigen receptor (CAR) T cell therapies, STK-009 + SYNCAR-001, IL13R CAR-T, GD3 CAR-T, c-KIT CAR-T, BCK – CART, EGFRv III-CART, Anti-EPCAM chimeric antigen receptor T-cell therapy, SNS-723, Research Program_CAR-T, SG295, SG239, SG242, DUAL CAR (CD19/CD20; Allogeneic CAR-T), DUAL CAR (BCMA/CD19; Allogeneic CAR-T), DUAL CAR (Undisclosed; Allogeneic CAR-T), OXB-302, Chimeric Antigen Receptor T cell therapy, and others.
- Out of the emerging CAR T therapies, JWCAR029 is in the late stage of development for Diffuse large B cell lymphoma and Follicular lymphoma treatment, whereas CT 103A is in the late stage of development for multiple myeloma.
- CAR T pipeline therapies in the mid-stage of development include MB-CART2019.1 for Diffuse large B cell lymphoma.
Request a sample and discover the recent advances in CAR T therapies @ CAR T Pipeline Insight and Outlook
CAR T Overview
CAR-T is a treatment in which a patient’s T cells (a type of immune system cell) are modified in the lab so that they will attack cancer cells. T cells are extracted from the blood of a patient. Then, in the laboratory, the gene for a particular receptor that attaches to a specific protein on the patient’s cancer cells is introduced to the T cells. The unique receptor is known as a chimeric antigen receptor (CAR). Many CAR T cells are produced in the laboratory and infused into the patient. CAR T-cell therapy is used to treat certain blood malignancies and is being researched for use in other forms of cancer. Chimeric antigen receptor T-cell therapy is another name for it.
For more information about CAR T-cell therapy drugs, visit: CAR T-cell Therapy Process
CAR T Pipeline Analysis: Drug Profile
JWCAR029: JW Therapeutics
JWCAR029 is a CAR-T cell product that targets CD19 and is designed to treat advanced lymphoma and leukaemia (Second-line therapy or greater). JWCAR029 is first being investigated for the treatment of B-cell malignancies, with a focus on relapsed and refractory DCBCL. The National Medical Products Administration (“NMPA”) accepted for review its NDA for relma-cel as a third-line treatment for DLBCL in June 2020.
CT 103A: Innovent Biologics
CT103A is a novel therapy that was co-developed by IASO BIO and Innovent. Previous research suggests that patients with relapsed/refractory multiple myeloma (RRMM) who received high-dose BCMA-targeting CAR-T cells may achieve better remission while experiencing more side effects. Furthermore, re-infusion of CAR-T cells is ineffective once the disease has progressed. The drug is currently preregistered for the treatment of multiple myeloma, according to the company’s pipeline.
Gain more knowledge on emerging CAR T-cell therapy drugs @ CAR T-cells for Cancer Therapy
Pipeline Therapies and Key Companies
- JWCAR029: JW Therapeutics
- CT 103A: Innovent Biologics
- CEA CAR T: Sorrento Therapeutics
- Descartes-11: Cartesian Therapeutics
- CTL119: Novartis
- TT11: Tessa Therapeutics
- CD19-targeted CAR-T cells: Sinobioway Cell Therapy
- MB-CART2019.1: Miltenyi Biomedicine
- EPCAM-targeted CAR T-cells: Sinobioway Cell Therapy
Learn more about the FDA approved CAR T cell therapy @ CAR T Clinical Trials
CAR T Pipeline Therapeutics Assessment
By Product Type
- Monotherapy
- Combination Therapy
By Stage
- Discovery
- Pre-Clinical
- Phase I
- Phase II
- Phase III
- Pre-registration
By Route of Administration
- Intravenous
- Intramuscular
- Subcutaneous
- Intratumoral
By Molecule Type
- T lymphocyte replacements
- Immunologic cytotoxicity
Scope of the Report
Coverage: Global
Key CAR T Companies: Ziopharm Oncology Inc. and Intrexon, Yake Biotechnology, Xyphos Biosciences, Xi’An Yufan Biotechnology, Wuhan Sian Medical Technology, Wuhan Bio-Raid Biotechnology, Wugen, WindMIL Therapeutics, Wellington Zhaotai Therapies, VorBio, VCANBIO Cell & Gene Engineering Corporation, Ltd, UWELL Biopharma, Transgene, TrakCel, ToolGen, Tmunity Therapeutics, Timmune Biotech, TILT Biotherapeutics, Tianjin Mycure Medical Technology, The Beijing Pregene Science and Technology Company, Tessa Therapeutics Ltd., TC BioPharm, Targazyme, Takeda, Noile-Immune Biotech, Synthekine, SymVivo, Sorrento Therapeutics, Sinobioway Cell Therapy Co., Ltd., Shenzhen BinDeBio, Shanghai Unicar-Therapy Bio-medicine Technology, Shanghai Longyao Biotechnology, Shanghai GeneChem Co., Ltd., Shanghai Biomed-union Biotechnology, Servier, Sensei Biotherapeutics, Senlang Bio, Sangamo, Sana Biotechnology, REGENERON, PTX Therapeutics, Protheragen, Pregene (ShenZhen) Biotechnology Company, Precision BioSciences, Precigen, Poseida Therapeutics, PersonGen BioTherapeutics (Suzhou) Co., Ltd., Pepromene bio, Oxford Biomedica, Orgenesis, Oncternal Therapeutics, Novartis Pharmaceuticals, Noile-Immune Biotech, Nanjing KAEDI Biotech, Mustang Bio, MolMed, Minerva Biotechnologies, Miltenyi Biotec, Medisix Therapeutics, Maxcyte, Luminary Therapeutics, Liminatus Pharma, Kuur Therapeutics, Kiromic BioPharma, Kecellitics Biotech Company Ltd, KAEDI, JW Therapeutics, Janssen Pharmaceuticals, Intellia Therapeutics, Innovent Biologics, Innovative Cellular Therapeutics, InnoBation, IN8Bio, Immunicum, Immuneel, Immune Therapeutics, iCell Gene Therapeutics, iCarTAB BioMed, Hunan Zhaotai Yongren Medical Innovation, Humorigin, HRAIN Biotechnology, Henan Hualong Biotechnology, Hemalogix, Helocyte, Helix BioPharma, Hebei Senlang Biotechnology Inc., Ltd., Guangzhou Bio-gene Technology, Guangdong Zhaotai InVivo Biomedicine Co. Ltd., Grand Vista Biotechnology, Gracell Biotechnology, Glycotype, GlaxoSmithKline, Gilead Sciences, Genus oncology, GC Cell, Fundamenta Therapeutics, Fujifilm Holdings Corporation, Formula Pharmaceuticals, Fate Therapeutics, FastBack Bio, Exuma, Eutilex, Utilities, Eureka Therapeutics, Enlivex Therapeutics Ltd, Endocyte, Elpis Biopharmaceuticals, Curocell, CRISPR Therapeutics, Creative Biolabs, Cogent Biosciences, Chongqing Precision Biotechnology Co., Ltd., Chimeric Therapeutics, Celyad Oncology SA, Cellular Biomedicine Group, Cellectis, Celgene, CASI Pharmaceuticals, Juventas Cell Therapy, Cartherics, Cartesian Therapeutics, Carsgen Therapeutics, CARsgen, Carina Biotech, Caribou Biosciences, Bristol-Myers Squibb, BrightPath Therapeutics, Bluebird Bio, Biosceptre, BioNTech, Bioceltech Therapeutics, Bioatla, Benitec Biopharma Limited , Bellicum Pharmaceuticals, Beijing Mario Biotech, Beijing Immunochina Medical Science and Technology, Beijing Doing Biomedical, Beam Therapeutics, Autolus Limited, Aurora Biopharma, Atreca, Xenor, Atossa Therapeutics, Atara Biotherapeutics, Arcellx Inc, Arbele Limited, Apceth Biopharma, Anixa Biosciences, Amgen, Kite Pharma, Allogene Therapeutics, Allife Medical Science and Technology, AgenTus Therapeutics, AffyImmune Therapeutics, Adicet Bio, Adagene, Actinium Pharmaceuticals, AbCLon, AbbVie, Obsidian Therapeutics, Beijing Biohealthcare Biotechnology, and others
Key CAR T Pipeline Therapies: JWCAR029, KTE-X19, Ciltacabtagene autoleucel, CT103A, CEA CAR-T, Descartes-11, CNCT19, CTL119, P-BCMA-101, CD19/CD20/CD22/CD30 CAR T-cell therapy, CD19-targeted CAR T-cells, EPCAM-targeted CAR-T cells, TT11, CD19+CD22 CAR-T cell sequential therapy, CART-19/22, MB-CART2019.1, JCAR017, AUTO4, AUTO3, IM19 CAR-T, CSG-CD19, CT053, Descartes-08, Orvacabtagene autoleucel, CAR-T CD30, PCAR-19B, BCMA CAR-T cells, CD123 CAR-T cells, CD19 CAR-T cells, ET140202, CIK-CAR.CD19, BG-T19, Autologous CD19-targeting CAR T cells (Senl-001), MB-102, Autologous CAR-T CD44v6 cell therapy, AU101, ATA2271, AU105, AUTO1, BPX-601, Anti-CD22 CAR, CAR-T cells targeting CD19 and CD22, huMNC2-CAR44 CAR T-cells, CD19-CART, ALLO-501A, AUTO1/22, ET 1402L1-CART, BPX-603, CAR-CD44v6, MB-106 (CD20 CAR), Anti-MUC1 CAR-T cells, PCAR-019, PBCAR0191, PBCAR20A, PBCAR269A, BCMA CAR T-cells, CAR19 CAR T cells, MG7-CART Cells, GPC3 – CART Cells, Anti-CD19 and Anti-CD20 CAR-T Cells, Humanized CD19 CAR-T cells, Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy, Mesothelin CAR-T cell therapy, TBI-1501, CART-19 cells, EGFR CART, CD19 Chimeric Antigen Receptor (CAR), BNT211, MB-CART19.1, MB-CART20.1, IM19 CAR-T, CD22 CAR-T, CAR-T, iC9-CAR19 cells, JCAR014, GC007g, CD-7 CAR-T Molecule, KD-025 CAR T cells, CD7 CAR T-cells infusion, CRC01, CT041, KD-182 CAR T cells, VCAR33, ICTCAR014, GC022F CAR-T cells, Senl_B19, IM21 CAR-T, CTX101, bb21217, CAR-GPC3, JCAR 018, JCAR020, JCAR024, CD19 Armored CAR, JCAR 023, UCART123, UCART22, UCARTCS1, CYAD-02, C-CAR011, CD20-CD19 Bispecific CAR, GC027, MB-103, UCART19, Cart19, Anti-BCMA CAR-T cell, CD19/CD20 bispecific CAR-T cells, AVA-001, Anti-CD19-CAR, P-PSMA-101, NIB-102, HER2-CAR VST + CAdVEC, CART-ddBCMA, CYAD-101, ET190L1 ARTEMIS, KITE-585, GPC3 targeting CAR-T cells, HER2/Mesothelin/Lewis-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T cell therapy, Triplex+CAR-Ts, Anti-CD19/BCMA Bispecific CAR T-cell Therapy, BCMA Chimeric Antigen Receptor Therapy, Human CD19 Targeted T-cells Injection Therapy, Anti-Meso CAR T cells, Anti-CD123 CAR T cells, Anti-CD22 CAR T cells, Zeushield Cytotoxic T Lymphocytes, CLL1b-CD33b compound CAR, CD19 CARvac cell therapy, BCMA-CD19 cCAR T cells therapy, Anti CD19 CART, Human anti-CD19, CD20 CAR T cells, Anti-CD19 Chimeric Antigen Receptor T cells (KD-019 CAR-T), GUCY2C-Targeted CAR-T Cells, CD19 CAR T-cells, CD70 CAR T-cells, IL3 CAR T-cells, CS1 Targeted CAR T-cells, Murine CD19 CAR T-cells, Humanized CD19 CAR T-cells, CD20/CD22 dual Targeted CAR T-cells, CART-meso, CART-EGFRvIII, CAR T-BCMA, cMet RNA CAR T, CART22 Therapy, BCMA-CART cells, Autologous chimeric antigen receptor T cell transfusing agent targeting CD22, Anti-CD20 CAR-T Cells, CD19 CAR-T cell therapy, Chimeric antigen receptor T cell, CD38 CAR-T, TT11X, Anti-CD19 chimeric antigen receptor T cell therapy, TMUN ONC 001, TMUN ONC 004, CD19 CAR T-cells, CD22 chimeric antigen receptor T cell therapy, CD19 2nd Generation CAR-T Cell Therapy, CD19 3rd Gen with mbIL15 (P-O-C), NKG2D CAR-T Cell Therapy, LMP1 CAR-T cells, APRIL CAR-T cells, CD79b CAR-T Cell Therapy, PRGN-3006, AIC100, ThisCART22, Iomab-ACT Program, ALLO-501, CYAD-211, MCY-M11, PSMA CAR-T -cell immunotherapy, Anti-CD20 CAR, CLBR001 + SWI019, Anti-BCMA CAR T cells, ALLO-715, PRGN-3005, XYF19 CAR-T cell, WU-CART-007, WZTL-002, TI 1007, KUR-501, KUR-502, GC012F, GC019F, GC007F, MB-104, MB-105, MB-101, Chimeric Antigen Receptor T Cell, CTX120, CTX130, BCMA Targeted CAR T-cells, CD19/BCMA Targeted CAR T-cells, TILT-123, CD4CAR, FT-819, CD19/CD20-directed CAR-T cells, CB-010, ALL0-316, ADI-001, KITE-222, JWCAR129, TAK-940, AMG 119, GPRC5D CAR T, Senl_1904B, TILT-T392, TZ-102, PMUC1C-101, P-BCMA-ALLO1, BAFF R CAR-T Cell, ATA3219, Solid Tumor Therapy Program (ovarian cancer), ALL0-605, TAA6-CAR-T, VOR33/ VCAR33, CAR (POC), Myeloid malignancies CAR-T Programme, Merck Target 1, Merck Target 2, Unnamed CAR target, Research programme: CRISPR gene-edited CAR-T cell therapeutics, TMUN ONC 003, IL13 Rα2 CAR-T, PSCA CAR-T, CAR-T Program, CD33HSC/CD33 CAR-T, FAP CAR-T, GPC2 CAR-T, TT14, TCB003, TCB004, TCB005, TCB006, NIB-103, Allogeneic chimeric antigen receptor (CAR) T cell therapies, STK-009 + SYNCAR-001, IL13R CAR-T, GD3 CAR-T, c-KIT CAR-T, BCK – CART, EGFRv III-CART, Anti-EPCAM chimeric antigen receptor T-cell therapy, SNS-723, Research Program_CAR-T, SG295, SG239, SG242, DUAL CAR (CD19/CD20; Allogeneic CAR-T), DUAL CAR (BCMA/CD19; Allogeneic CAR-T), DUAL CAR (Undisclosed; Allogeneic CAR-T), OXB-302, Chimeric Antigen Receptor T cell therapy, and others
Table of Contents
| 1. | CAR T Pipeline Report Introduction |
| 2. | CAR T Pipeline Report Executive Summary |
| 3. | CAR T Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | CAR T Pipeline Therapeutics |
| 6. | CAR T Pipeline: Late Stage Products (Pre-registration) |
| 7. | CAR T Pipeline: Late Stage Products (Phase III) |
| 8. | CAR T Pipeline: Mid Stage Products (Phase II) |
| 9. | CAR T Pipeline: Early Stage Products (Phase I) |
| 10. | CAR T Pipeline Therapeutic Assessment |
| 11. | Inactive Products in the CAR T Pipeline |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products in the CAR T Pipeline |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
Got queries? Reach out for more information @ CAR T Pipeline Assessment
Related Reports
CAR T-cell Therapy for Acute Lymphoblstic Leukemia Market
CAR T-cell Therapy for Acute Lymphoblastic Leukemia Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CAR T-cell therapy for acute lymphoblastic leukemia companies including Autolus, Pepromene Bio, Actinium Pharmaceuticals, among others.
CAR T-cell Therapy for Multiple Myeloma Market
CAR T-cell Therapy for Multiple Myeloma Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CAR T-cell therapy for multiple myeloma companies including Novartis, Yake Biotech, Celgene Corporation, among others.
CAR T-cell Therapy for Non Hodgkin’s Lymphoma Market
CAR T-cell Therapy for Non Hodgkin’s Lymphoma Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CAR T-cell therapy for non hodgkin’s lymphoma companies including Juno Therapeutics, Allogene Therapeutics, Caribou Biosciences, among others.
CAR T-cell Therapy for Acute Lymphoblstic Leukemia Pipeline
CAR T-cell Therapy for Acute Lymphoblastic Leukemia Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key CAR T-cell therapy for acute lymphoblastic leukemia companies including Autolus, Pepromene Bio, Actinium Pharmaceuticals, among others..
CAR T-cell Therapy for Multiple Myeloma Pipeline
CAR T-cell Therapy for Multiple Myeloma Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key CAR T-cell therapy for multiple myeloma companies, including Novartis, Yake Biotech, Celgene Corporation, among others.
CAR T-cell Therapy for Non Hodgkin’s Lymphoma Pipeline
CAR T-cell Therapy for Non Hodgkin’s Lymphoma Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key CAR T-cell therapy for non hodgkin’s lymphoma companies, including Juno Therapeutics, Allogene Therapeutics, Caribou Biosciences, among others.
Other Trending Reports
Atopic Dermatitis Market | Peripheral Vascular Devices Market | Obsessive-Compulsive Disorder Market | Sinus Dilation Devices Market | Papilloma Market | Germ Cell Tumor Market | Portal Hypertension Market | Cell And Gene Therapy For Multiple Myeloma Market | Fallopian Tube Cancer Market | Atherectomy Devices Market | Oncolytic Virus Cancer Therapy Market | Urinary Incontinence Market | Cholangiocarcinoma Market | Tissue Heart Valves/Cardiovascular Prosthetic Devices Market | Artificial Disc Market | Obesity Market | Cerebral Infarction Market | Hematuria Market | Diabetes Market | Spinal Fusion Devices Market | Panuveitis Market | Prosthetic Heart Valve Market
Latest Healthcare Blogs
- Bronchopulmonary Dysplasia Treatment Market
- RVO Market Beyond Lucentis and Eylea
- Role of Nanobots in Healthcare
- Wilson’s Disease Pipeline Therapies
- denovoSkin – Personalized Skin Grafts for Burn Treatment
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Contact Us
Sandeep Joshi
info@delveinsight.com
+1(919)321-6187